Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

NCT02106585 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: JTT-251 or Placebo

Sponsor

Akros Pharma Inc.